Meeting
2019 ASCO Annual Meeting
Treatment sequence in elderly metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in a prospective cohort study.
Authors
Maria Jose Mendez-Vidal
Reina Sofía University Hospital, Cordoba, Spain
Maria Jose Mendez-Vidal , Rebeca Lozano , Elena Castro , Nuria Romero-Laorden , Alejo Rodriguez-Vida , Nuria Lainez , Amaia Hernandez , Rosa Villatoro , Francisco Zambrana , Jose Carlos Villa Guzman , Rocío García Domínguez , Saray Galvan Ruiz , Ricardo Escribano , Enrique Gallardo Díaz , Rosa Querol , Raquel Luque , Aránzazu Gonzalez del Alba , Javier Puente , David Olmos , David Lorente
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 37, 2019 (suppl; abstr 5053)
DOI
10.1200/JCO.2019.37.15_suppl.5053
Abstract #
5053
Poster Bd #
165
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
Impact of treatment sequence in metastatic castration-resistant prostate cancer (mCRPC) on outcome in a prospective cohort study.
First Author: Rebeca Lozano
Poster
2020 Genitourinary Cancers Symposium
The effect of treatment sequence on overall survival for men with metastatic castration-resistant prostate cancer: A multicenter retrospective study.
First Author: Shingo Hatakeyama
Poster
2019 Genitourinary Cancers Symposium
Correlation between time to PSA progression (TTPP), radiographic progression-free survival (rPFS) and overall survival (OS) in first-line abiraterone/enzalutamide (Abi/Enza) and docetaxel (Doc) treated patients in a prospective cohort study.
First Author: David Lorente
Poster
2023 ASCO Genitourinary Cancers Symposium
Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS–Meet-URO 26 study.
First Author: Vincenzo Gennusa